New X Post from OBD shown below;
"We are thrilled to announce that our EpiSwitch® NST blood test has been shown to accurately detect both #colorectalcancer and polyps. A multi-institutional study, now published in the peer-reviewed journal @Cancers_MDPI, confirms its clinical efficacy. Discussions are underway with potential partners to bring this breakthrough test to clinical practice. Read more: obdx.co/7sc'"
Read more on X;
@OxBioDynamics
To be fair it only finished at 0.50p because of a small UT sell at 0.498p at 4.35pm
Will be a big week on the back of that news and once the market digests it all
Also, Unicorn fund have been selling down but now they seem to be OUT. See RNS today |
This is why this market stinks Get in and get out that's it |
Strange action today.At one point up over 65% and finished Red.Placement was done at 0.50 and with todays cancer early discovery news, I find the market incredible that less value is aligned to the company than before todays announcement! Go figure. |
So these have had a 7M placing in early Jan and news like that comes out and it's up 10% it's nuts :o |
60% up to level, market makers disgusting |
It ought to on that news, crazy markets! |
Can see this running up big today ;) |
Some real thickos on lse who missed the boat this morning |
I've added from 0.55 to 0.65 Now loadedIt's crazy cheapThink more news will come |
volume is king!!!
and OBD have it today with news. |
huge buying!!! |
Huge volume day coming MMS will start to push up regardless of placing flippers who want to sell fineBut overall this is a huge news absolutely Huge |
PmslThe news is the news It's positive and they are cashed up |
Way too much placing stock to shift |
Volume 81 million now. |
Easy 1p from here. |
It's crazy how the mms work. When they need to offload a placing they race away up with the share price on genuine good news they seem lack lustre |
Oxford BioDynamics' EpiSwitch® CRC Blood Test AccuratelyDetects both Cancer and Polyps
· Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics' EpiSwitch® blood-based Colorectal No-Stool Test (NST)
· High accuracy of detection reported at 81% for early cancer stages and 82% for non-cancerous polyps
· Discussions are underway with potential partners to bring this potentially evolutionary test to clinical practice |
Great volume, almost 60 million. |
surprised only 15% up, on Nasdaq it would have been 100% up already. |
Huge news here |
Oxford BioDynamics' EpiSwitch® CRC Blood Test AccuratelyDetects both Cancer and Polyps
· Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics' EpiSwitch® blood-based Colorectal No-Stool Test (NST)
· High accuracy of detection reported at 81% for early cancer stages and 82% for non-cancerous polyps
· Discussions are underway with potential partners to bring this potentially evolutionary test to clinical practice |
Where’s that fool boysie 72 🤡📉🕳️€169; |
How did Iain Ross's turnaround at RENE go
Soiled his record (so far) |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
